MaxCyte Stock

MaxCyte FCF per Share

The Free Cash Flow per Share of MaxCyte (MXCT) as of Sep 5, 2026 is -0.28 USD. In the previous year, Free Cash Flow per Share was -0.25 USD — a change of 13.53% (lower).

FCF per Share

-0.28USD

YoY

13.53%

Last updated:

Free Cash Flow per Share of MaxCyte is 2026 -0.28 USD. Free Cash Flow per Share of MaxCyte was 2025 -0.25 USD. It decreases by 13.53% lower compared to the previous year.

The MaxCyte FCF per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF per Share
Date
FCF per Share
Jan 1, 2017
-0.21 USD
Jan 1, 2018
-0.22 USD
Jan 1, 2019
-0.18 USD
Jan 1, 2020
-0.16 USD
Jan 1, 2021
-0.16 USD
Jan 1, 2022
-0.33 USD
Jan 1, 2023
-0.25 USD
Jan 1, 2024
-0.28 USD
The MaxCyte FCF per Share history
YEARFCF per ShareYoY
-0.28USD+13.53%
-0.25USD-24.83%
-0.33USD+104.25%
-0.16USD+2.51%
-0.16USD-12.51%
-0.18USD-18.41%
-0.22USD+3.44%
-0.21USD+177.00%
-0.08USD+1,129.59%
-0.01USD-87.02%
-0.05USD—
Access this data via the Eulerpool API
Get Free API Key

MaxCyte Stock analysis

What does MaxCyte do? MaxCyte Inc is a US biotechnology company specializing in the development of platform-based technologies for the next generation of gene and cell therapies. They offer integrated platform technology for drug manufacturing, research, and development. Their proprietary platform technology, Flow ElectroporationTM, allows for efficient transduction of a variety of cells, making it a valuable tool for the production of CAR-T cell therapies. They also offer services for lentiviral production and customized gene therapy production. MaxCyte has secured $50 million in funding for expansion and has formed important partnerships in the industry. They are a leading player in the development of innovative technologies for gene and cell therapy products. MaxCyte is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MaxCyte stock

Free Cash Flow per Share of MaxCyte is -0.28 USD in 2026.

Free Cash Flow per Share of MaxCyte changed from -0.25 USD to -0.28 USD, representing a 13.53% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow per Share MaxCyte since 2006 – with annual values, charts, and detailed analysis.

FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.

Access this data via the Eulerpool API
Get Free API Key

Cash Flow — MaxCyte

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — MaxCyte